Hanall Biopharma Co., Ltd. (009420.KS) KSC

Currency In KRW

AD

Valuation

Market Cap2.18T
Enterprise Value2.19T
P/E Ratio-90.03
PEG Ratio-0.14
Price/Sales Ratio13.57
Price/Book Ratio13.96
Enterprise/Revenue13.62
Enterprise/EBITDA-156.85

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterMarch 31, 2026

Profitability

Profit Margin-0.15
Operating Margin0.03
AD

Management Effectiveness

Return On Assets-0.1
Return On Equity-0.16

Income Statement

Revenue155.18B
Revenue/Share3,113.64
Gross Profit79.1B
EBITDA1.94B
Net Income-5.56B
Diluted EPS-111.55

Balance Sheet

Total Cash36.16B
Total Cash/Share692.14
Total Debt44.2B
Total Debt/Equity0.27
Current Ratio1.6
Book Value Per Share3,107.85

Price History

52-Week Change65.65
52-Week High73,000
52-Week Low25,550
Moving Average 50 Days53,984
Moving Average 200 Days49,779

Statistics

Average Volume544,043
Shares Outstanding50.86M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split Factor10:1
Last Split DateMay 03, 2006
AD